CN115120591A - 一种peg化喜树碱长效缓释凝胶 - Google Patents
一种peg化喜树碱长效缓释凝胶 Download PDFInfo
- Publication number
- CN115120591A CN115120591A CN202210926877.8A CN202210926877A CN115120591A CN 115120591 A CN115120591 A CN 115120591A CN 202210926877 A CN202210926877 A CN 202210926877A CN 115120591 A CN115120591 A CN 115120591A
- Authority
- CN
- China
- Prior art keywords
- camptothecin
- pegylated
- peg
- solution
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DZNNFZGDBUXWMV-ZUWDIFAMSA-N 581079-18-7 Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(OC(=O)[C@H](C)NC(=O)COCCOCC(=O)N[C@@H](C)C(=O)O[C@@]3(CC)C5=C(C(N6CC7=CC8=CC=CC=C8N=C7C6=C5)=O)COC3=O)CC)C4=NC2=C1 DZNNFZGDBUXWMV-ZUWDIFAMSA-N 0.000 title claims abstract description 20
- 238000013268 sustained release Methods 0.000 title claims description 17
- 239000012730 sustained-release form Substances 0.000 title claims description 16
- 239000003814 drug Substances 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 238000011065 in-situ storage Methods 0.000 claims abstract description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 60
- 229940127093 camptothecin Drugs 0.000 claims description 53
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 46
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 45
- 239000000243 solution Substances 0.000 claims description 44
- 238000002360 preparation method Methods 0.000 claims description 28
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- -1 alkyl aldehyde Chemical class 0.000 claims description 17
- 108010039918 Polylysine Proteins 0.000 claims description 14
- 229920000656 polylysine Polymers 0.000 claims description 14
- 229920002873 Polyethylenimine Polymers 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 5
- 125000003172 aldehyde group Chemical group 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 150000003934 aromatic aldehydes Chemical class 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 abstract description 7
- 238000006731 degradation reaction Methods 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 123
- 239000000499 gel Substances 0.000 description 67
- 239000003153 chemical reaction reagent Substances 0.000 description 34
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 32
- 229940079593 drug Drugs 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- 229910021538 borax Inorganic materials 0.000 description 8
- 239000000017 hydrogel Substances 0.000 description 8
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 8
- 235000019799 monosodium phosphate Nutrition 0.000 description 8
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 8
- 239000004328 sodium tetraborate Substances 0.000 description 8
- 235000010339 sodium tetraborate Nutrition 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 235000002597 Solanum melongena Nutrition 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 description 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VXWYQEYFYNAZOD-UHFFFAOYSA-N 2-[3-[(4,4-difluoropiperidin-1-yl)methyl]-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound FC1(F)CCN(CC2=NN(CC(=O)N3CCC4=C(C3)N=NN4)C=C2C2=CN=C(NC3CC4=C(C3)C=CC=C4)N=C2)CC1 VXWYQEYFYNAZOD-UHFFFAOYSA-N 0.000 description 1
- VNPMDUDIDCXVCH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(3-piperazin-1-ylpropyl)pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound O=C(CN1C=C(C(CCCN2CCNCC2)=N1)C1=CN=C(NC2CC3=C(C2)C=CC=C3)N=C1)N1CCC2=C(C1)N=NN2 VNPMDUDIDCXVCH-UHFFFAOYSA-N 0.000 description 1
- ISCMYZGMRHODRP-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=N ISCMYZGMRHODRP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000759905 Camptotheca acuminata Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2371/00—Characterised by the use of polyethers obtained by reactions forming an ether link in the main chain; Derivatives of such polymers
- C08J2371/02—Polyalkylene oxides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2477/00—Characterised by the use of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Derivatives of such polymers
- C08J2477/04—Polyamides derived from alpha-amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2479/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen, or carbon only, not provided for in groups C08J2461/00 - C08J2477/00
- C08J2479/02—Polyamines
Abstract
本发明公开了一种PEG化喜树碱衍生物,具有如下结构:
Description
技术领域
本发明属于医药化工领域,具体涉及一种PEG化喜树碱衍生物及其与多氨基化合物交联形成的长效缓释凝胶。
背景技术
喜树碱由1966年美国的Monroe E.Wall博士从喜树的皮中分离得到,其在抗肿瘤活性上的优异表现引起了人们的广泛关注。它可以选择性抑制拓扑异构酶Ⅰ,与TopoⅠ-DNA形成的复合物结合,稳定此复合物,从而使断裂的DNA链不能重新接合,阻止DNA复制及RNA合成,为细胞周期S期特异性药物。另外,它还能直接破坏DNA结构。实验证明,喜树碱对多种动物肿瘤有抑制作用,与常用抗肿瘤药物无交叉耐药。但是,其分子结构中喹琳环上氮的特殊碱性导致其水溶性差,不能直接用于人体的非肠道给药。同时由于喜树碱副作用大,体内半衰期短,体内残留时间长等缺点,使得其应用受到一定的限制。
与以往的常规剂型如片剂、胶囊、注射剂相比,缓释、控释制剂能够减少给药次数,改善患者的顺应性。尤其针对的是半衰期短的或者需要频繁给药的药物,可以减少服药次数,使药物浓度平稳,避免峰谷现象,有利于降低药物的毒副作用,增加药物治疗的稳定性和安全性。同时可以减少用药的总量,用较少的剂量达到更好的效果。
现有技术通过物理包埋或化学修饰方式,增强喜树碱的水溶性,延长消除时间,起到降低毒性提高药效的作用。
CN101352420B通过膜乳化法制备了装载羟基喜树碱的缓释微球,该专利制备的缓释微球能通过微导管直接在瘤体内注射方式给药,可实现靶向给药,降低枪击喜树碱的全身毒副作用,可以在体内存留30天左右。但其制备过程需要用到有机溶剂,对人体存在一定的刺激性。
CN106236699B介绍了“溶液喷涂”或“热熔挤出”工艺两种制备装载10-羟基喜树碱的体内植入物的制备方法,通过该方法制备植入剂能在体内缓慢释放HCPT,增强HCPT的药物作用,降低不良反应。同时植入剂能够直接与肿瘤接触,增加了肿瘤局部的药物浓度,降低了血中的药物浓度。但是该发明描述制备工艺复杂,且无法如微球药剂一样通过注射的方法植入体内,药物释放量较少,实际使用效果不理想。
CN101156854A通过将喜树碱及其衍生物组装在不同高分子层数的微胶囊中,以达成药物缓释的效果。该发明工艺简单,使用材料均为可降解材料,制备过程不存在化学反应,对人体影响较小。但该药剂在15小时左右就可以达到40%的药物释放率,药物释放太快,容易引起药物毒副作用。
相比于喜树碱药物,PEG化喜树碱注射液,可以显著提高药物的水溶性,实现体内较长时间的循坏。临床试验显示,PEG化喜树碱在体内的半衰期可以达到77小时左右(Rowinsky EK等人,J Clin Oncol 21:148–157)。然而临床实验中,仍然需要多次给药以维持足够的药物浓度,而且全身给药会给健康器官带来较大的全身毒性。通过物理包埋凝胶可实现局部给药,以提高药物在肿瘤局部的浓度来降低药物的全身毒性,然而对于小分子喜树碱药物来说,药物从凝胶中的释放速率较快,难以达到长期缓释的目的,例如喜树碱在琼脂凝胶的释放周期仅为两个小时左右(J.Liu et al./European Polymer Journal 42(2006))。因此,为了提高喜树碱药物的抗肿瘤能力,迫切需要一种能在肿瘤局部长期缓释药物的方法。
发明内容
本发明针对现有技术不足,提供了一种PEG化喜树碱衍生物以及该PEG化喜树碱衍生物与多氨基化合物原位交联形成的可注射性凝胶。可随着凝胶的降解实现药物缓慢释放,达到长期缓释药物的目的。
本发明具体技术方案如下:
优选的,所述醛基封端的星形多臂聚乙二醇的臂数为2-8,单臂分子量1000-5000Da。
所述醛基选自芳香醛、烷基醛中的一种或几种,所述醛基与星形多臂聚乙二醇之间以酯键、醚键、酰胺键、氨酯键、亚胺键或脲键化学键连接,优选酰胺键或酯键连接。
本发明另一目的在于提供一种PEG化喜树碱缓释凝胶,由本发明所述的PEG化喜树碱衍生物和多氨基化合物原位交联而成。
优选的,所述多氨基化合物中氨基与PEG化喜树碱衍生物中醛基的摩尔比为0.4~4.4:1,更优选1~4:1;所述多氨基化合物为聚赖氨酸或聚赖氨酸与聚乙烯亚胺的混合物,聚赖氨酸与聚乙烯亚胺的摩尔比为2~30:3,更优选2~10:3。
本发明所述的PEG化喜树碱缓释凝胶,采用如下方法制备而成:将PEG化喜树碱衍生物溶解在pH4-6缓冲液中,配制溶液;将多氨基化合物溶解在pH4-10缓冲液中,配制多氨基化合物溶液;将两者混合得到PEG化喜树碱缓释凝胶。
所述PEG化喜树碱衍生物溶液的质量体积百分浓度为2-30%,优选,10~20%;所述多氨基化合物溶液质量体积百分浓度为0.5-20%,优选1-5%。
本发明另一目的在于提供本发明所述的PEG化喜树碱衍生物或PEG化喜树碱在制备抗癌缓释药物中的应用。
本发明优点:
本发明通过可降解连接键将喜树碱偶联在PEG上,同时通过PEG端基功能化进一步与多氨基化合物化学偶联,实现原位凝胶。本发明所述PEG化喜树碱凝胶具有长效缓释作用,显著减少药物突释,药物随降解而缓慢释放,周期长达一到三个月。
附图说明
图1为不同桥接链长的PEG化喜树碱凝胶的药物缓释曲线。
图2为不同取代率的PEG化喜树碱凝胶的药物缓释曲线。
图3为不同取代率的PEG化喜树碱凝胶的在37℃的溶胀曲线。
具体实施方式
以下通过实施例说明本发明的具体步骤,但不受实施例限制。在本发明中所使用的术语,除非另有说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例并参照数据进一步详细描述本发明。应理解,这些实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。在以下实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
实施例1 CPT-OOC(CH2)2COOH的合成
称取喜树碱(CPT-OH,174mg)、丁二酸酐(150mg)于50mL茄瓶中,再加入1,8-二氮杂双环[5.4.0]十一碳-7-烯(DBU,0.23mL),二氯甲烷(DCM)15mL,室温反应4h。加入盐酸水溶液猝灭反应,再加入大量二氯甲烷萃取,柱层析分离,得浅黄色粉末状固体114mg。1H NMR(400MHz,DMSO-d6,)δ12.17(s,1H),8.69(s,1H),8.18(d,J=8.5Hz,1H),8.13(d,J=8.2Hz,1H),7.91–7.82(m,1H),7.72(t,J=7.5Hz,1H),7.13(s,1H),5.48(s,2H),5.30(s,2H),2.84–2.67(m,2H),2.47(m,2H),2.15(q,J=7.4Hz,2H),0.91(t,J=7.4Hz,3H).HRMS(positive ESI)m/z found(calcd for C24H20N2O7+H+):449.1344(449.1343).HRMS(positive ESI)m/z found(calcd for C24H20N2O7-H+):447.1198(447.1198)。
实施例2 CPT-OOC(CH2)3COOH的合成
称取喜树碱(CPT-OH,174mg)、戊二酸酐(171mg)于50mL茄瓶中,再加入1,8-二氮杂双环[5.4.0]十一碳-7-烯(DBU,0.23mL),二氯甲烷(DCM)15mL,室温反应4h。加入盐酸水溶液猝灭反应,再加入大量二氯甲烷萃取,柱层析分离,得浅黄色粉末状固体85mg。1H NMR(400MHz,DMSO-d6,)δ12.00(s,1H),8.66(s,1H),8.16–8.08(m,2H),7.83(ddd,J=8.4,6.8,1.5Hz,1H),7.68(ddd,J=8.0,6.8,1.3Hz,1H),7.02(s,1H),5.46(s,2H),5.27(s,2H),2.54(t,J=7.4Hz,2H),2.27(t,J=7.4Hz,2H),2.15–2.08(m,2H),1.73(q,J=7.4Hz,2H),0.88(t,J=7.4Hz,3H).HRMS(positive ESI)m/z found(calcd for C25H22N2O7+H+):463.1499(463.1500)。
实施例3 CPT-OOC(CH2)4COOH的合成
称取喜树碱(CPT-OH,174mg)、己二酸(219mg)、4-二甲氨基吡啶(DMAP,183mg)、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCI,576mg)于50mL茄瓶中,再加入二氯甲烷(DCM)15mL,室温反应12h。加入盐酸水溶液猝灭反应,再加入大量二氯甲烷萃取,柱层析分离,得浅黄色粉末状固体165mg。1H NMR(400MHz,DMSO-d6)δ11.97(s,1H),8.70(s,1H),8.19–8.12(m,2H),7.87(ddd,J=8.4,6.9,1.5Hz,1H),7.72(ddd,J=8.1,6.8,1.3Hz,1H),7.07(s,1H),5.49(s,2H),5.30(s,2H),2.54(d,J=6.6Hz,2H),2.24(t,J=6.7Hz,2H),2.16(m,2H),1.57(m,4H),0.92(t,J=7.4Hz,3H).HRMS(positive ESI)m/z found(calcd forC26H24N2O7+H+):477.1656(477.1656)。
实施例4 CPT-OOC(CH2)5COOH的合成
称取喜树碱(CPT-OH,174mg)、庚二酸(240mg)、4-二甲氨基吡啶(DMAP,183mg)、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCI,576mg)于50mL茄瓶中,再加入二氯甲烷(DCM)15mL,室温反应12h。加入盐酸水溶液猝灭反应,再加入大量二氯甲烷萃取,柱层析分离,得浅黄色粉末状固体135mg。1H NMR(400MHz,DMSO-d6)δ11.94(s,1H),8.70(s,1H),8.20–8.11(m,2H),7.86(ddd,J=8.5,6.9,1.5Hz,1H),7.72(ddd,J=8.1,6.8,1.2Hz,1H),7.05(s,1H),5.49(s,2H),5.31(s,2H),2.59–2.51(m,2H),2.16(tt,J=8.8,5.4Hz,4H),1.61–1.49(m,4H),1.34(q,J=7.8Hz,2H),0.92(t,J=7.4Hz,3H).HRMS(positive ESI)m/zfound(calcd for C27H26N2O7+H+):491.1812(491.1813)。
实施例5 CPT-OOC(CH2)6COOH的合成:
称取喜树碱(CPT-OH,174mg)、辛二酸(261mg)、4-二甲氨基吡啶(DMAP,183mg)、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐(EDCI,576mg)于50mL茄瓶中,再加入二氯甲烷(DCM)15mL,室温反应12h。加入盐酸水溶液猝灭反应,再加入大量二氯甲烷萃取,柱层析分离,得浅黄色粉末状固体96mg。1H NMR(400MHz,DMSO-d6)δ11.88(s,1H),8.66(s,1H),8.11(t,J=9.1Hz,2H),7.83(t,J=7.7Hz,1H),7.68(t,J=7.5Hz,1H),7.01(s,1H),5.45(s,2H),5.27(s,2H),2.50(m,2H),2.11(m,4H),1.52(q,J=7.3Hz,2H),1.41(t,J=7.3Hz,2H),1.26(m,4H),0.88(t,J=7.4Hz,3H).HRMS(positive ESI)m/z found(calcd for C28H28N2O7+H+):505.1969(505.1969)。
表1为实施例1-5具有不同连接键长的喜树碱衍生物的最大紫外吸收波长及吸光系数,结果表明对喜树碱的修饰未影响其它官能团结构。
表1 CPT-OOC(CH2)nCOOH的紫外吸收统计
实施例6 PEG-(OH)7(CPT)1的合成
称量1.00g PEG(OH)8(八臂星形聚乙二醇,单臂分子量1875Da)原料,分别将实施例1-5合成的喜树碱二酸酐衍生物,0.311g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.294g 4-二甲氨基吡啶加入到30mL二氯甲烷(DCM)中,常温搅拌12h。将反应溶液稀释于250mL DCM中,用250mL氯化钠水溶液水洗三次,接着浓缩后在乙醚中沉淀。最后,将得到的固体样品真空抽干称重得到产物。
实施例7 PEG-(p-phCHO)7(OOC(CH2)2COOCPT)1的合成
将1.20g实施例6制得的PEG-(OH)7(OOC(CH2)2COOCPT)1,0.217g对甲酰基苯甲酸,0.374g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.353g 4-二甲氨基吡啶加入到30mL二氯甲烷(DCM)中,常温搅拌12h。将反应溶液稀释于250mL DCM中,用250mL氯化钠水溶液水洗三次,接着浓缩后在乙醚中沉淀。最后,将得到的固体样品真空抽干称重得0.835g产物。
实施例8 PEG-(p-phCHO)7(OOC(CH2)3COOCPT)1的合成
将1.20g实施例6制得的PEG-(OH)7(OOC(CH2)3COOCPT)1,0.217g对甲酰基苯甲酸,,0.374g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.353g 4-二甲氨基吡啶加入到30mL二氯甲烷(DCM)中,常温搅拌12h。将反应溶液稀释于250mL DCM中,用250mL氯化钠水溶液水洗三次,接着浓缩后在乙醚中沉淀。最后,将得到的固体样品真空抽干称重得0.735g产物。
实施例9 PEG-(p-phCHO)7(OOC(CH2)4COOCPT)1的合成
将1.653g实施例6制得的PEG-(OH)7(OOC(CH2)4COOCPT)1,0.298g对甲酰基苯甲酸,0.515g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.486g 4-二甲氨基吡啶加入到30mL二氯甲烷(DCM)中,常温搅拌12h。将反应溶液稀释于250mL DCM中,用250mL氯化钠水溶液水洗三次,接着浓缩后在乙醚中沉淀。最后,将得到的固体样品真空抽干称重得1.234g产物。
实施例10 PEG-(p-phCHO)7(OOC(CH2)5COOCPT)1的合成
将1.587g实施例6制得的PEG-(OH)7(OOC(CH2)5COOCPT)1,0.287g对甲酰基苯甲酸,,0.494g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.466g 4-二甲氨基吡啶加入到30mL二氯甲烷(DCM)中,常温搅拌12h。将反应溶液稀释于250mL DCM中,用250mL氯化钠水溶液水洗三次,接着浓缩后在乙醚中沉淀三次。最后,将得到的固体样品真空抽干称重得0.922g产物。
实施例11 PEG-(p-phCHO)7(OOC(CH2)6COOCPT)1的合成
将1.498g实施例6制得的PEG-(OH)7(OOC(CH2)6COOCPT)1,0.275g对甲酰基苯甲酸,0.466g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.440g 4-二甲氨基吡啶加入到30mL二氯甲烷(DCM)中,常温搅拌12h。将反应溶液稀释于250mL DCM中,用250mL氯化钠水溶液水洗三次,接着浓缩后在乙醚中沉淀三次。最后,将得到的固体样品真空抽干称重得0.967g产物。
实施例12 PEG-(OH)6(OOC(CH2)3COOCPT)2的合成
反应方程式:
将CPT-OOC(CH2)3COOH(206.8mg)、PEG(OH)8(3.89g)、EDCI(4.887g)和DMAP(2.926g),放入圆底烧瓶中,加入二氯甲烷溶剂30ml,反应室温搅拌过夜。然后萃取水洗3次,并在乙醚中沉淀。最终得到产物2.9g。
其中,化学位移为δ8.7,8.15,7.87,7.72,7.06为CPT芳基氢,δ5.50,5.31为CPT中亚甲基CH2的氢,δ2.15,0.92为CPT中CH2CH3的氢,δ2.60,2.40,1.79为CPT-OOC(CH2)3COO的CH2CH2CH2的氢,δ4.59为PEG羟基的峰,δ4.11为PEG中与羧基酯化生成的COOCH2的氢。
实施例13 PEG-(p-phCHO)6(OOC(CH2)3COOCPT)2的合成
将2.059g实施例12制得的喜树碱衍生物PEG-(OH)6(OOC(CH2)3COOCPT)2,0.588g对甲酰基苯甲酸(p-CBA),1.009g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.962g4-二甲氨基吡啶加入到二氯甲烷(DCM)中,搅拌12h。将反应溶液稀释于约250mL DCM中,用水洗三次,旋蒸浓缩后在乙醚中沉淀,最后,将得到的固体样品真空抽干称重得0.880g产物。
实施例14 PEG-(OH)4(OOC(CH2)3COOCPT)4的合成
反应方程式:
将CPT-OOC(CH2)3COOH(415.8mg,)、PEG(OH)8(3.99g,)、EDCI(7.668g,)和DMAP(5.8664g,48mmol),放入圆底烧瓶中,加入二氯甲烷溶剂30ml,反应室温搅拌过夜。然后萃取水洗3次,并在乙醚中沉淀。最终得到产物3.6g。
其中,化学位移为δ8.7,8.15,7.87,7.72,7.06为CPT芳基氢,δ5.50,5.31为CPT中亚甲基CH2的氢,δ2.15,0.92为CPT中CH2CH3的氢,δ2.60,2.40,1.79为CPT-OOC(CH2)3COO的CH2CH2CH2的氢,δ4.59为PEG羟基的峰,δ4.11为PEG中与羧基酯化生成的COOCH2的氢。
实施例15 PEG-(p-phCHO)4(OOC(CH2)3COOCPT)4的合成
将2.035g实施例14制得的喜树碱衍生物PEG-(OH)4(OOC(CH2)3COOCPT)4、0.370g对甲酰基苯甲酸(p-CBA),0.666g 1-乙基-(3-二甲基氨基丙基)碳酰二亚胺(EDC)和0.634g4-二甲氨基吡啶加入到二氯甲烷(DCM)中,搅拌12h。将反应溶液稀释于约250mL DCM中,用水洗三次,旋蒸浓缩后在乙醚中沉淀,最后,将得到的固体样品真空抽干5h后称重得0.880g产物。
表2为实施例7~11和实施例15偶联苯醛基及喜树碱的PEG的H NMR关键化学位移,从化学位移比例关系确认了取代率,该工艺能精准的调控药物及交联官能团的比例。
表2 PEG-(p-phCHO)n(OOC(CH2)nCOOCPT)n的H NMR结果统计
实施例16水凝胶制备
配制方法:800mg实施例7制得的PEG-(p-phCHO)7(OOC(CH2)2COOCPT)1溶于3.2mlpH5.6磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8mlpH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例17水凝胶制备
配制方法:800mg实施例8制得的PEG-(p-phCHO)7(OOC(CH2)3COOCPT)1溶于3.2mlpH5.6磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8mlpH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例18水凝胶制备
配制方法:800mg实施例9制得的PEG-(p-phCHO)7(OOC(CH2)4COOCPT)1溶于3.2mlpH5.6磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8mlpH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例19水凝胶制备
配制方法:800mg实施例10制得的PEG-(p-phCHO)7(OOC(CH2)5COOCPT)1溶于3.2mlpH5.6磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8mlpH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例20水凝胶制备
配制方法:800mg实施例11制得的PEG-(p-phCHO)7(OOC(CH2)6COOCPT)1溶于3.2ml0.1pH5.6M磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8ml pH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例21水凝胶制备
配制方法:800mg实施例13制得的PEG-(p-phCHO)6(OOC(CH2)3COOCPT)2溶于3.2mlpH5.6磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8mlpH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例22水凝胶制备
配制方法:800mg实施例15制得的PEG-(p-phCHO)4(OOC(CH2)3COOCPT)4溶于3.2mlpH5.6磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8mlpH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例23水凝胶制备
配制方法:800mg PEG-(p-phCHO)8和4mgCPT溶于3.2ml pH5.6磷酸二氢钠水溶液中配制凝胶试剂A,50mg聚乙烯亚胺和100mg聚赖氨酸溶于3.8ml pH9.2硼砂缓冲液中配制凝胶试剂B。
凝胶制作过程:先组装好三个方块模具,用注射器分别抽取等体积试剂A和试剂B,装上双联注射架上,迅速将溶液混合打入模具,即可得到凝胶。
实施例24考察本发明所述PEG化喜树碱凝胶的药物缓释行为
将实施例16-22以及实施例23制得的凝胶称重,加入10倍PBS缓冲液,置于37℃水浴摇床中,定期取浸提液,紫外测试吸光度值,利用喜树碱紫外吸收标准曲线计算浸提液中喜树碱含量。
不同桥接链长的PEG化喜树碱凝胶的药物释放曲线如图1所示。结果显示仅物理包埋喜树碱的凝胶(实施例23),在前24小时药物突释达到80%,3天就完全释放。而本发明所述不同桥接链长的PEG化喜树碱凝胶(实施例17~19)实现了长效的缓释。
不同取代率的PEG化喜树碱凝胶的药物释放曲线如图2所示。结果表明,不同取代率的PEG化喜树碱凝胶(实施例17、21、22)对缓释无直接影响,可依据临床药物用量需求,选择不同取代率的PEG化喜树碱凝胶。
实施例25考察本发明所述PEG化喜树碱凝胶的降解行为
将实施例16-23制得的凝胶称重,加入10倍PBS缓冲液,置于37℃水浴摇床中,定期取凝胶称称重,与初始重量比对,计算凝胶溶胀率。结果如图3所示。结果表明,喜树碱取代率高的凝胶降解速度较快,约为2个月,喜树碱取代率低的凝胶更为稳定,降解时间超过3个月。降解速率快慢与喜树碱取代率高低具有正相关性,可以根据临床不同肿瘤治疗周期制备不同喜树碱取代率的凝胶。
实施例26考察本发明所述PEG化喜树碱的成胶时间
将实施例16-23制得的凝胶试剂A和试剂B分别吸100微升,依次加入小瓶中,等体积混合,从试剂A、B接触开始计时,采用倒管法观察混合溶液的流动,直到不流动时及为成胶时间。
结果如表3所示。结果表明不同桥接链长不影响PEG化喜树碱凝胶的注射及成型。
表3 PEG化喜树碱凝胶成胶时间
实施例 | 凝胶中药物分子 | 成胶时间(秒) |
实施例17 | PEG-(p-phCHO)<sub>7</sub>(OOC(CH<sub>2</sub>)<sub>3</sub>COOCPT)<sub>1</sub> | 5 |
实施例18 | PEG-(p-phCHO)<sub>7</sub>(OOC(CH<sub>2</sub>)<sub>4</sub>COOCPT)<sub>1</sub> | 6 |
实施例19 | PEG-(p-phCHO)<sub>7</sub>(OOC(CH<sub>2</sub>)<sub>5</sub>COOCPT)<sub>1</sub> | 4 |
实施例20 | PEG-(p-phCHO)<sub>7</sub>(OOC(CH<sub>2</sub>)<sub>6</sub>COOCPT)<sub>1</sub> | 6 |
实施例23 | PEG-(p-phCHO)<sub>8</sub> | 5 |
Claims (10)
2.根据权利要求1所述的PEG化喜树碱衍生物,其特征在于n代表2~6的正整数。
3.根据权利要求1所述的PEG化喜树碱衍生物,其特征在于所述醛基封端的星形多臂聚乙二醇的臂数为2-8,单臂分子量1000-5000Da。
4.根据权利要求1所述的PEG化喜树碱衍生物,其特征在于所述醛基选自芳香醛、烷基醛中的一种或几种。
5.一种PEG化喜树碱缓释凝胶,其特征在于由权利要求1-4任一项所述的PEG化喜树碱衍生物和多氨基化合物原位交联而成。
6.根据权利要求5所述的PEG化喜树碱缓释凝胶,其特征在于所述多氨基化合物中氨基与PEG化喜树碱衍生物中醛基的摩尔比为0.4~4.4:1,所述多氨基化合物为聚赖氨酸或聚赖氨酸与聚乙烯亚胺的混合物,聚赖氨酸与聚乙烯亚胺的摩尔比为2~30:3。
7.根据权利要求5所述的PEG化喜树碱缓释凝胶,其特征在于采用如下方法制备而成:将PEG化喜树碱衍生物溶解在pH4-6缓冲液中,配制溶液;将多氨基化合物溶解在pH4-10缓冲液中,配制多氨基化合物溶液;将两者混合得到PEG化喜树碱缓释凝胶。
8.根据权利要求7所述的PEG化喜树碱缓释凝胶,其特征在于所述PEG化喜树碱衍生物溶液的质量体积百分浓度为2-30%,所述多氨基化合物溶液质量体积百分浓度为0.5-20%。
9.根据权利要求8所述的PEG化喜树碱缓释凝胶,其特征在于所述PEG化喜树碱衍生物溶液的质量体积百分浓度为10~20%,所述多氨基化合物溶液的质量体积百分浓度为1-5%。
10.权利要求1-4任一项所述的PEG化喜树碱衍生物或权利要求5-9任一项所述的PEG化喜树碱缓释凝胶在制备抗癌缓释药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210926877.8A CN115120591A (zh) | 2022-08-03 | 2022-08-03 | 一种peg化喜树碱长效缓释凝胶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210926877.8A CN115120591A (zh) | 2022-08-03 | 2022-08-03 | 一种peg化喜树碱长效缓释凝胶 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115120591A true CN115120591A (zh) | 2022-09-30 |
Family
ID=83386687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210926877.8A Pending CN115120591A (zh) | 2022-08-03 | 2022-08-03 | 一种peg化喜树碱长效缓释凝胶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115120591A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101530619A (zh) * | 2009-04-16 | 2009-09-16 | 山东大学 | 一种水溶性聚乙二醇化羟基喜树碱衍生物的制备方法 |
CN102204881A (zh) * | 2011-06-08 | 2011-10-05 | 复旦大学 | 含喜树碱或其衍生物的凝胶缓释注射剂及其制备方法 |
CN109939065A (zh) * | 2018-08-10 | 2019-06-28 | 上海瑞凝生物科技有限公司 | 医用水凝胶 |
-
2022
- 2022-08-03 CN CN202210926877.8A patent/CN115120591A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101530619A (zh) * | 2009-04-16 | 2009-09-16 | 山东大学 | 一种水溶性聚乙二醇化羟基喜树碱衍生物的制备方法 |
CN102204881A (zh) * | 2011-06-08 | 2011-10-05 | 复旦大学 | 含喜树碱或其衍生物的凝胶缓释注射剂及其制备方法 |
CN109939065A (zh) * | 2018-08-10 | 2019-06-28 | 上海瑞凝生物科技有限公司 | 医用水凝胶 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Tumor microenvironment-labile polymer–doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma | |
CN102060991B (zh) | 7-乙基-10-羟基喜树碱的两亲性药物前体及其制备方法 | |
CN102276813B (zh) | 含叶酸靶向高分子药物载体及其制备方法 | |
KR20050065595A (ko) | 히알루론산 또는 히알루론산 유도체에 공유적으로 결합된탁산 | |
CN105727309A (zh) | 双敏感两亲性多糖-阿霉素偶联物及其药学组合物的制备和应用 | |
CN107669626B (zh) | 一种高载药量的还原敏感的药物传递系统的制备方法及其应用 | |
CN111437258B (zh) | 基于交联生物可降解聚合物囊泡的抗肿瘤纳米佐剂及其制备方法与应用 | |
CN105859990B (zh) | 侧链含硫辛酰基的聚合物、其制备方法及由其制备的聚合物囊泡及其应用 | |
Heyder et al. | Poly (anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy | |
Jing et al. | Oral pectin/oligochitosan microspheres for colon-specific controlled release of quercetin to treat inflammatory bowel disease | |
CN115120591A (zh) | 一种peg化喜树碱长效缓释凝胶 | |
CN109464676A (zh) | 一种壳寡糖光敏靶向纳米粒的制备方法及产品 | |
CN105832668A (zh) | 基于聚磷酸酯的叶酸靶向酸敏感核交联载药胶束 | |
Rodríguez-Acosta et al. | Polymer-dendrimer hybrids as carriers of anticancer agents | |
CN111671917B (zh) | 一种石蒜碱纳米粒、其制备方法及应用 | |
CN110025574A (zh) | 一种还原响应型两亲性聚合物药物前体及其制备方法和应用 | |
Liu et al. | Using polypeptide bearing furan side chains as a general platform to achieve highly effective preparation of smart Glycopolypeptide analogue-based Nano-prodrugs for Cancer treatment | |
CN117777378A (zh) | 一种具有pH和氧化还原双重刺激响应型聚合物载体的制备方法及应用 | |
CN105687135B (zh) | 一类杂合型肿瘤靶向纳米胶束及其用途 | |
CN108939091A (zh) | 一种含有香豆素单元的pH响应性的交联胶束及其制备方法与应用 | |
CN108283720A (zh) | 同时键合喜树碱和阿霉素的聚磷酸酯前药及其制备方法与应用 | |
CN110483756B (zh) | 末端含硫辛酰基的星型聚合物的制备方法及聚合物纳米粒子的制备方法 | |
CN115611926B (zh) | 非敏感键桥连的sn38二聚体前药及其自组装纳米粒和应用 | |
CN113908289B (zh) | 一种具有精确调控药物比例的抗肿瘤多元载药体系及其制备方法 | |
EP3858330A1 (en) | Hyperbranched polyester polyol derivative as drug solubilizer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |